These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35430592)

  • 1. Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies.
    Kevlicius L; Cepulyte R; Vasilevska D; Griskevicius L; Zucenka A
    Bone Marrow Transplant; 2022 Jun; 57(6):1034-1037. PubMed ID: 35430592
    [No Abstract]   [Full Text] [Related]  

  • 2. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
    Desikan SP; Ravandi F; Pemmaraju N; Konopleva M; Loghavi S; Jabbour EJ; Daver N; Jain N; Chien KS; Maiti A; Montalban-Bravo G; Kadia TM; Macaron W; DeLumpa R; Kwari M; Borthakur G; Short NJ
    Acta Haematol; 2022; 145(5):529-536. PubMed ID: 35717939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
    Nachmias B; Aumann S; Haran A; Schimmer AD
    Br J Haematol; 2024 Apr; 204(4):1146-1158. PubMed ID: 38296617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 6. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
    Karol SE; Alexander TB; Budhraja A; Pounds SB; Canavera K; Wang L; Wolf J; Klco JM; Mead PE; Das Gupta S; Kim SY; Salem AH; Palenski T; Lacayo NJ; Pui CH; Opferman JT; Rubnitz JE
    Lancet Oncol; 2020 Apr; 21(4):551-560. PubMed ID: 32171069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS; Bradshaw D; Abaza Y; Murthy GSG; Palmisiano N; Zeidan AM; Kota V; Litzow MR
    Blood Cancer J; 2024 Feb; 14(1):32. PubMed ID: 38378617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
    Madero-Marroquin R; Dworkin E; Weiner H; Saygin C; Nawas MT; Drazer MW; DuVall AS; Kosuri S; Thirman MJ; Odenike O; Stock W; Larson RA; Patel AA
    Leuk Lymphoma; 2024 Jun; 65(6):864-867. PubMed ID: 38441062
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
    Maiti A; Rausch CR; Cortes JE; Pemmaraju N; Daver NG; Ravandi F; Garcia-Manero G; Borthakur G; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Kadia TM; Takahashi K; Yilmaz M; Jain N; Kornblau S; Montalban Bravo G; Sasaki K; Andreeff M; Bose P; Ferrajoli A; Issa GC; Jabbour EJ; Masarova L; Thompson PA; Wang S; Konoplev S; Pierce SA; Ning J; Qiao W; Welch JS; Kantarjian HM; DiNardo CD; Konopleva MY
    Haematologica; 2021 Mar; 106(3):894-898. PubMed ID: 32499238
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
    Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
    J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Ferrara F
    Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
    [No Abstract]   [Full Text] [Related]  

  • 12. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
    Steinauer N; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar AA; Saliba AN; Torghabeh M; Litzow MR; Hogan WJ; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Yi CA; Tefferi A; Gangat N
    Haematologica; 2024 Aug; 109(8):2706-2710. PubMed ID: 38546692
    [No Abstract]   [Full Text] [Related]  

  • 13. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
    Bewersdorf JP; Giri S; Wang R; Williams RT; Tallman MS; Zeidan AM; Stahl M
    Haematologica; 2020 Nov; 105(11):2659-2663. PubMed ID: 33131256
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia.
    Qu W; Lu J; Ji Y; He Z; Hou M; Li D; Yang Y; Liu D; Chen S
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):635-639. PubMed ID: 38430306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
    Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
    Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

  • 18. Venetoclax in acute myeloid leukemia.
    Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Investig Drugs; 2023 Apr; 32(4):271-276. PubMed ID: 36933006
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity of venetoclax against relapsed acute undifferentiated leukemia.
    Caldwell KJ; Budhraja A; Opferman JT; Pui CH; Klco JM; Rubnitz JE
    Cancer; 2021 Aug; 127(15):2608-2611. PubMed ID: 33823069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
    Jamy O; Lin K; Worth S; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R
    Br J Haematol; 2022 Aug; 198(3):e35-e37. PubMed ID: 35509246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.